| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | bACE1 |
| Uniprot No | P56817 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 22-460aa |
| 氨基酸序列 | TQHGIRLPLR SGLGGAPLGL RLPRETDEEP EEPGRRGSFV EMVDNLRGKS GQGYYVEMTV GSPPQTLNIL VDTGSSNFAV GAAPHPFLHR YYQRQLSSTY RDLRKGVYVP YTQGKWEGEL GTDLVSIPHG PNVTVRANIA AITESDKFFI NGSNWEGILG LAYAEIARPD DSLEPFFDSL VKQTHVPNLF SLQLCGAGFP LNQSEVLASV GGSMIIGGID HSLYTGSLWY TPIRREWYYE VIIVRVEING QDLKMDCKEY NYDKSIVDSG TTNLRLPKKV FEAAVKSIKA ASSTEKFPDG FWLGEQLVCW QAGTTPWNIF PVISLYLMGE VTNQSFRITI LPQQYLRPVE DVATSQDDCY KFAISQSSTG TVMGAVIMEG FYVVFDRARK RIGFAVSACH VHDEFRTAAV EGPFVTLDME DCGYNIPQTD ESTLMTIAY |
| 预测分子量 | 50 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于bACE1重组蛋白的3篇示例文献(内容为模拟，实际文献需进一步检索验证)：
---
1. **文献名称**：*Expression and Purification of Recombinant Human BACE1 in Insect Cells for Structural Studies*
**作者**：Vassar, R. et al.
**摘要**：报道了利用杆状病毒-昆虫细胞系统表达人源bACE1重组蛋白的方法，优化了纯化流程并获得高纯度蛋白，用于后续X射线晶体学分析，揭示了其催化位点的结构特征。
2. **文献名称**：*Functional Characterization of Recombinant bACE1 in Amyloid-β Production*
**作者**：Sinha, S. et al.
**摘要**：通过哺乳动物细胞(HEK293)表达重组bACE1.验证其切割淀粉样前体蛋白(APP)的活性，证明其在阿尔茨海默病病理中的关键作用，并建立体外酶活检测体系。
3. **文献名称**：*Development of a Prokaryotic Expression System for bACE1 and Screening of Inhibitors*
**作者**：Hong, L. et al.
**摘要**：利用大肠杆菌(E. coli)表达可溶性bACE1重组蛋白，通过包涵体复性获得活性酶，并基于此建立高通量抑制剂筛选平台，发现多个潜在小分子抑制剂。
---
**提示**：实际文献可通过PubMed或Sci-Hub等平台搜索关键词(如"recombinant BACE1 expression"、"BACE1 purification")获取。需要具体文献可提供更详细的研究方向!
**Background of bACE1 Recombinant Protein**
β-site amyloid precursor protein cleaving enzyme 1 (BACE1), also known as beta-secretase 1. is a transmembrane aspartic protease critical in the pathogenesis of Alzheimer’s disease (AD). It catalyzes the rate-limiting step in the production of amyloid-beta (Aβ) peptides by cleaving the amyloid precursor protein (APP). Accumulation of Aβ plaques in the brain is a hallmark of AD, making BACE1 a prominent therapeutic target.
The recombinant form of BACE1 (bACE1) is engineered for research and drug discovery. It is typically expressed in mammalian or insect cell systems to ensure proper post-translational modifications and enzymatic activity. Recombinant bACE1 retains the functional domains of the native enzyme, including the catalytic site, enabling in vitro studies on substrate specificity, inhibitor screening, and mechanistic investigations.
Research on bACE1 has driven the development of BACE1 inhibitors aimed at reducing Aβ production. However, challenges such as poor blood-brain barrier penetration and off-target effects have limited clinical success. Recombinant bACE1 facilitates structural studies (e.g., X-ray crystallography) to design selective inhibitors and understand resistance mechanisms.
Beyond AD, bACE1 is implicated in other neurological and metabolic processes, though its physiological roles remain partially unclear. Recombinant protein tools also aid in exploring these non-pathological functions. Additionally, bACE1 serves as a biomarker in diagnostic assays to evaluate disease progression or therapeutic efficacy.
In summary, recombinant bACE1 is a vital resource for advancing AD research, drug development, and understanding protease biology, bridging gaps between cellular studies and clinical applications.
×
